November 14 from 12:30 am – 1:15 pm EST
Please join Dr. Sudhakar Tumuluri as he provides an overview of OFEV pivotal safety and efficacy data and examines a case study to highlight the importance of identifying appropriate patients for treatment with OFEV.
This program is developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc. This is not an official program of the American College of Rheumatology. Onsite registration will occur for conference registrants only at the program entrance on a first-come, first-served basis. Presentation content has been reviewed for consistency with FDA guidelines and is not approved for continuing education credit. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals, attendance at this promotional program is limited to healthcare professionals, attendance by healthcare professionals’ spouses or guests is not permitted.
Sudhakar Tumuluri, MD
Redwood City, California